Although both benralizumab and mepolizumab were associated with a decline in eosinophil counts, a deeper, more significant reduction was observed in the benralizumab treatment arm at all 3 time ...

Suggested remit: To appraise the clinical and cost effectiveness of benralizumab within its marketing authorisation for previously treated severe nasal polyps.

TUESDAY, Dec. 10, 2024 (HealthDay News) -- Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

First breakthrough in treating asthma attacks in 50 years hailed as a ‘game-changer’ Benralizumab is a monoclonal antibody that targets specific white blood cells ...

A new treatment for asthma attacks is being described as “game-changing” by the London scientists who created it. The drug, which is called benralizumab, is the first new treatment for asthma ...

London scientists have created a “game-changing” new treatment for asthma attacks that can reduce the need for further treatment by 30 per cent. Benralizumab is the first treatment for asthma attacks ...

The drug, which is called benralizumab, is the first new treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. A trial has shown that using the drug can cut the ...